SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Shlepper who wrote (1443)10/18/1998 8:27:00 PM
From: yosi s  Respond to of 1491
 
Israeli Regulatory agency will be reluctant to approve a drug that was not approve in Europe or Israel.
Study needs to be completed.
I agree with David that HU211 has greater than 80% chance of making it through phase 3 .

But if they miss,.. well ...back to the drawing board.



To: Shlepper who wrote (1443)10/18/1998 10:10:00 PM
From: David Israel-Rosen  Read Replies (1) | Respond to of 1491
 
Dear Shlepper:

PARS is not a marketing company. I doubt that they will do anything before FDA approval of HU211


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News